CN1813779A - Use of naringin for preparing medicine for preventing cold - Google Patents
Use of naringin for preparing medicine for preventing cold Download PDFInfo
- Publication number
- CN1813779A CN1813779A CN 200510101404 CN200510101404A CN1813779A CN 1813779 A CN1813779 A CN 1813779A CN 200510101404 CN200510101404 CN 200510101404 CN 200510101404 A CN200510101404 A CN 200510101404A CN 1813779 A CN1813779 A CN 1813779A
- Authority
- CN
- China
- Prior art keywords
- naringin
- group
- influenza
- virus
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an application of naringin in preparation of medicine for preventing and curing influenza. The naringin has the good action for resisting influenza virus. Said invention has obvious therapeutic effect for curing influenza due to virus.
Description
Technical field
The present invention relates to naringin as the purposes of preventing and treating the influenza medicine.
Background technology
Influenza is a kind of acute respiratory infectious disease, and very strong infectiousness is arranged.Existing epidemiologic data demonstration once was very popular every about 10 years.Influenza breaks out, distributes, popularly then take place frequently in all parts of the world, and the serious threat people are the health and the life of old people and other high-risk group such as the chronic heart, pneumonopathy or diabetics especially.The traditional therapy of influenza is suitably to have a rest and symptomatic treatment, is the inevitable development of treatment means but treat at cause of disease, is an important topic of study of pharmacy to the research that prevents and treats the influenza medicine always.
The structural formula of naringin:
Summary of the invention
The purpose of this invention is to provide naringin as the purposes of preventing and treating the influenza medicine.
The present invention confirms that through in vitro tests naringin has the obvious suppression effect to influenza virus.
The antivirus test result shows in the animal body: naringin has good inhibitory effect to influenza virus in the mice body.
We adopt the single oral administration, the toxic reaction that the maximum dosage that allows on the observational technique is produced mice by the reagent thing.The result shows: the maximal dose single oral administration of naringin to allow, mice does not see toxic reaction.
In sum, illustrate that naringin has good resisiting influenza virus effect, do not see toxic and side effects, therefore, can be used for preparing the medicine of preventing and treating influenza.
The specific embodiment
The present invention is described further below in conjunction with embodiment.
Embodiment 1. naringins are to the cytopathogenic inhibitory action of influenza virus
In the MDCK culture bottle, inoculate 100TCID
508 concentration behind (median tissue culture infective dose) viral liquid doubling dilution were hatched 2 hours for 37 ℃, added 2 times of 7 variable concentrations releasing dilution of maximal non-toxic concentration liquid after HankShi liquid washes 2 times, saw Table 1.Continue to cultivate 3 days for 37 ℃, every day, the observation of cell pathological changes and was done the hemagglutinative titer test.Establish virazole positive controls, virus control and cell blank contrast simultaneously, 4 bottles in every sample, experimental result sees Table.Each medication group is to A
3With the Type B influenza virus certain inhibitory action is arranged all, naringin group (1: 4) can suppress Type B virus institute cytopathogenic effect fully.Can produce partial inhibition to first 3 influenza virus cytopathogenic effects, naringin (1: 4) is to producing the obvious suppression effect greater than 1: 8 dilution virogenetic cytopathy.
Table 1 naringin is to A
3Type and the cytopathogenic inhibitory action of Type B influenza virus
| Group | The medicine dilution is released | Cytopathy | |||||||
| 1 | 1∶2 | 1∶4 | 1∶8 | 1∶16 | 1∶32 | 1∶64 | 1∶128* | ||
| Virus (B) | - | ++++ | ++++ | ++++ | ++++ | ++++ | ++++ | ++ | + |
| Groups of cells | - | - | - | - | - | - | - | - | - |
| Virazole | 0.25 | - | - | - | - | - | - | - | - |
| The naringin group | 1∶4 | - | - | - | - | - | - | - | - |
| The naringin group | 1∶8 | ++++ | +++ | + | - | - | - | - | - |
| The naringin group | 1∶16 | ++++ | +++ | ++ | - | - | - | - | - |
| The naringin group | 1∶32 | ++++ | +++ | ++++ | +++ | - | - | - | - |
| The naringin group | 1∶64 | ++++ | ++++ | ++++ | ++++ | +++ | - | - | - |
| Virus (A 3) | - | ++++ | ++++ | ++++ | ++++ | ++++ | ++++ | ++ | + |
| Groups of cells | - | - | - | - | - | - | - | - | - |
| Virazole | 0.25 | ++++ | ++++ | +++ | +++ | ++ | - | - | - |
| The naringin group | 1∶4 | ++++ | ++ | ++ | - | - | - | - | - |
| The naringin group | 1∶8 | ++++ | +++ | ++ | + | - | - | - | - |
| The naringin group | 1∶16 | ++++ | ++++ | ++ | ++ | - | - | - | - |
| The naringin group | 1∶32 | ++++ | ++++ | ++++ | ++++ | ++ | ++ | - | - |
| The naringin group | 1∶64 | ++++ | +++ | +++ | +++ | +++ | +++ | ++ | ++ |
* be " viral dilution degree "; Naringin is made into the stock solution of 6mg/ml; Virazole 0.25mg/ml
Embodiment 2. naringin interior resisting virus are tested
Adopt A
3It is model that type influenza virus liquid inductance dyes mice, observes low dosage and is subjected to reagent thing, middle dosage to be subjected to reagent thing, high dose to be subjected to the influence to Lung Index of mice infected by Influenza virus, pneumonopathy range degree of reagent thing, positive control medicine (virazole).The results are shown in Table 2, the result shows: be subjected to basic, normal, high three the dosage groups of reagent thing all can significantly suppress pneumonopathy range degree, lung index and model control group relatively have significant difference statistically, and prompting is subjected to the reagent thing to have the interior anti-A of body preferably
3The effect of type influenza virus.
Table 2 naringin is to the inhibitory action of influenza virus
| Group | n | Dosage (mg/kg) | The lung index | Suppression ratio (%) |
| The virus control group | 10 | - | 1.29±0.166 | - |
| The virazole group | 10 | 80 | 1.07±0.16 | 17.0 |
| The naringin low dose group | 10 | 20 | 1.05±0.20 | 18.4 |
| Dosage group in the naringin | 10 | 40 | 1.02±0.17 | 21.2 |
| The naringin high dose group | 10 | 80 | 1.07±0.12 | 16.8 |
Embodiment 3. acute toxicity test in mice
Adopt the single oral administration, the toxic reaction that the maximum dosage that allows on the observational technique is produced mice by the reagent thing.The result shows: after being subjected to the administration of reagent thing 13.33g/kgbw single oral, mice is movable normal, and no abnormality seens such as outward appearance, behavior, secretions, Excreta change.Observed 14 days continuously, there is no abnormal response, duration of test, the weight of animals normal growth cuts open inspection after the observation period finishes and does not find the unusual pathological change of histoorgan.Prompting: be subjected to the maximal dose 13.33g/kgbw single oral administration of reagent thing to allow, mice does not see toxic reaction.
Embodiment 4. naringin tablets
Be prepared into tablet by following composition proportion:
Naringin 250g
Starch 225g
Starch slurry (14%) 13g
Micropowder silica gel 22g
Make 1000 altogether
With naringin and starch uniform mixing, add starch slurry and stir the system soft material, to granulate, dry back adds micropowder silica gel, granulate, tabletting is made 1000 altogether, and every heavily is about 0.5g.
Claims (1)
1. naringin is used for preventing and treating the application of influenza medicine in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510101404 CN1813779A (en) | 2005-11-23 | 2005-11-23 | Use of naringin for preparing medicine for preventing cold |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510101404 CN1813779A (en) | 2005-11-23 | 2005-11-23 | Use of naringin for preparing medicine for preventing cold |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1813779A true CN1813779A (en) | 2006-08-09 |
Family
ID=36906211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510101404 Pending CN1813779A (en) | 2005-11-23 | 2005-11-23 | Use of naringin for preparing medicine for preventing cold |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1813779A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322700B (en) * | 2007-06-13 | 2010-08-25 | 中国科学院生物物理研究所 | Applications of naringenin and naringin as signal pathway inhibitor of transforming growth factor-beta 1 |
| CN102264222B (en) * | 2008-11-04 | 2014-12-10 | 威麦迪克有限责任公司 | Antiviral supplement formulations |
-
2005
- 2005-11-23 CN CN 200510101404 patent/CN1813779A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101322700B (en) * | 2007-06-13 | 2010-08-25 | 中国科学院生物物理研究所 | Applications of naringenin and naringin as signal pathway inhibitor of transforming growth factor-beta 1 |
| CN102264222B (en) * | 2008-11-04 | 2014-12-10 | 威麦迪克有限责任公司 | Antiviral supplement formulations |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zandi et al. | Antiviral activity of Aloe vera against herpes simplex virus type 2: An in vitro study | |
| Reynolds et al. | Viral inhibitors derived from macroalgae, microalgae, and cyanobacteria: A review of antiviral potential throughout pathogenesis | |
| Allegra et al. | Vitamin deficiency as risk factor for SARS-CoV-2 infection: correlation with susceptibility and prognosis. | |
| CN101455736B (en) | Use of wild jujube seeds extract | |
| CN1316968C (en) | Application of indole-2,3-diketone in preparing medication for antivirus or immunopotenfiator | |
| CN101836952A (en) | Ambroxol injection and preparation method thereof | |
| CN111135184A (en) | Application of GS-441524 in preparation of novel coronavirus SARS-CoV-2 inhibitor | |
| Zheng et al. | Oral administration of exopolysaccharide from Aphanothece halophytica (Chroococcales) significantly inhibits influenza virus (H1N1)-induced pneumonia in mice | |
| CN1548056A (en) | Application of chitin, chitosan and their derivatives in preparing antiviral | |
| CN110327246A (en) | A kind of mouthwash containing marine oligosaccharide | |
| CN101862357B (en) | Acute turpinia leaf general flavone ethanol reflux extract, and preparation method and application thereof | |
| CN1813779A (en) | Use of naringin for preparing medicine for preventing cold | |
| CN102772398A (en) | Application of dihydromyricetin in preparation of drug preventing and treating influenza | |
| Stefanou et al. | Pomegranate as an anti-viral agent and immune system stimulant | |
| CN1679926A (en) | Use of human lysozyme in preparing anti-virus medicines for influenza | |
| CN105381024A (en) | Pharmaceutical composition for treating chicken coccidiosis and preparation method thereof | |
| CN101797266B (en) | Pharmaceutical composition containing quercetin and usage thereof | |
| CN105267211B (en) | Aspochalasin classes compound prepare AntiHIV1 RT activity hide drug and treat AIDS-treating medicine in application | |
| CN102935098A (en) | Acute turpinia leaf general flavone ethanol reflux extract, and preparation method and application thereof | |
| CN113440562B (en) | Application of compound houttuynia cordata mixture in preparation of medicine for preventing or treating coronavirus | |
| CN106039164A (en) | Traditional Chinese medicine powder for treating coccidiosis in chicken and preparation method of traditional Chinese medicine powder for treating coccidiosis in chicken | |
| CN103070876B (en) | The compositions that the anti-encephalitis b virus of one class infects and application thereof | |
| CN113730573A (en) | Antiviral composition and application thereof | |
| CN102920751A (en) | Turpinia arguta leaf total flavonoid ethanol reflux extract, preparation method and uses thereof | |
| CN117462572A (en) | Broad-spectrum antiviral composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |